| Description | This mouse neutralizing antibody is specific against CVB1 capsid protein. It binds mainly to the viral VP2 domain of CVB1 capsid protein. The mAb exhibits potent neutralizing activity against CVB1 and it inhibits CAR binding to the virus in a dose-dependent manner. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | Coxsackievirus B1 (CVB1) |
| Epitope | The VP2 domain |
| Neutralization Mechanism | The antibody binding footprints closely encircle the canyon region and overlap with the CAR-binding site. |
| Neutralization Breath | The middle dosage (0.1 mg/kg) of the mAb offered 75% protection against lethal challenge. |
| IC50 | 0.376 μg/mL |
| Affinity | 240.5 ± 236.6 nM |
| Isotype | Mouse IgG |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein G purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; SPR; IF; Neut |
| Application Notes | Immunofluorescence (IF): After blocking with 2% bovine serum albumin (BSA) diluted in PBS, cells were incubated with mAbs (5 μg/mL) at 37°C for 1 h. Neutralization assay (Neut): MAbs was 2-fold serially diluted and incubated with an equal volume of CVB1 at 37°C for 1 h. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | CVB1 VP2 |
| Alternative Name | Coxsackievirus B1 capsid protein |
| Research Area | Infectious Disease |
| Related Disease | Aseptic meningitis; myocarditis; pancreatitis |
